Brio Consultants LLC Sells 436 Shares of Bio-Rad Laboratories, Inc. $BIO

Brio Consultants LLC trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 33.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 863 shares of the medical research company’s stock after selling 436 shares during the quarter. Brio Consultants LLC’s holdings in Bio-Rad Laboratories were worth $208,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. First Eagle Investment Management LLC raised its stake in Bio-Rad Laboratories by 60.7% during the 2nd quarter. First Eagle Investment Management LLC now owns 2,517,313 shares of the medical research company’s stock worth $607,478,000 after buying an additional 951,123 shares during the period. First Pacific Advisors LP grew its stake in Bio-Rad Laboratories by 136.0% in the first quarter. First Pacific Advisors LP now owns 372,555 shares of the medical research company’s stock valued at $90,739,000 after acquiring an additional 214,705 shares during the period. Ariel Investments LLC increased its holdings in shares of Bio-Rad Laboratories by 29.3% in the first quarter. Ariel Investments LLC now owns 724,660 shares of the medical research company’s stock worth $176,498,000 after acquiring an additional 164,136 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Bio-Rad Laboratories by 17.5% during the first quarter. Dimensional Fund Advisors LP now owns 877,040 shares of the medical research company’s stock worth $213,608,000 after purchasing an additional 130,921 shares during the period. Finally, Mawer Investment Management Ltd. lifted its holdings in shares of Bio-Rad Laboratories by 14.8% during the 1st quarter. Mawer Investment Management Ltd. now owns 294,879 shares of the medical research company’s stock valued at $71,821,000 after purchasing an additional 37,952 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $305.07 on Friday. The stock has a market capitalization of $8.26 billion, a price-to-earnings ratio of -12.55 and a beta of 1.04. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $373.69. The firm has a fifty day simple moving average of $300.02 and a 200 day simple moving average of $267.61. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 EPS for the quarter, missing the consensus estimate of $2.30 by ($0.04). Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.The business had revenue of $653.00 million for the quarter, compared to the consensus estimate of $651.30 million. During the same period last year, the firm earned $2.01 earnings per share. The company’s quarterly revenue was up .5% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BIO has been the subject of a number of research reports. Citigroup increased their target price on Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Wall Street Zen raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. Royal Bank Of Canada raised their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Wells Fargo & Company upped their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings upgraded Bio-Rad Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, October 30th. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $358.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.